A B S T R A C T Patients with active systemic lupus erythematosus (SLE) often have circulating antibodies to T cells. These patients also often have leukopenia and diminished numbers of T lymphocytes. In addition, certain T lymphocyte functions are frequently impaired in patients with SLE. It has been previously considered that a complement-dependent cytotoxic mechanism was responsible for the above observations. We now demonstrate that antibody-dependent cellmediated cytotoxicity (ADCC), a cytotoxic reaction mediated by antibody and effector cells in the absence of complement, can also kill T cells from normal individuals as well as from patients with SLE. Moreover, this ADCC could be observed using the plasma, effector cells, and target cells all obtained from the same individual with SLE.
INTRODUCTION
The sera or plasma from some patients with systemic lupus erythematosus (SLE)1 contain antibodies directed against normal leukocytes, especially when the disease is active. These antibodies are thought to be related to the leukopenia observed in many patients with active SLE. Their existence has been demonstrated by a variety of methods such as antiglobulin tests, complementdependent cytotoxicity (CDC) assays (1) , and immunofluorescence techniques (2, 3) . The studies to date have indicated that some of these antibodies are reactive with T lymphocytes and that these antibodies are ofthe IgG, IgA, and the IgM classes (2) (3) (4) . Anti-lymphocytic antibodies of the IgM class are especially efficient at mediating complement-dependent lymphocytotoxicity (5, 6) . In general, IgG antibodies tend to be inefficient in assays employing CDC or immunofluorescence with live cells. However, IgG antibodies can be detected after elution from living cells, by their ability to inhibit mixed lymphocyte reactions (7), or by immunofluorescent techniques using fixed cells (2, 4, 8) .
Recently there has been great interest in the regulation ofthe immune response, particularly with regard to functional activities of particular T cell subsets (9) (10) (11) (12) (13) (14) (15) . Some investigators have proposed that anti-T cell antibodies could be responsible for decreased function of suppressor cells (16) (17) (18) . New Zealand mice with a lupus-like syndrome have antibodies to T cells and decreased T cell functions, and have also been reported to have a loss of T suppressor function (19) (20) (21) . Sakane et al. (22) showed that IgM anti-lymphocyte antibodies from patients with active SLE, in the presence of complement, preferentially killed suppressor cell precursors; therefore, the loss of suppressor T cells in patients with SLE may (in part, or entirely) be the result of the effects of such antibody activity.
Although much information now exists regarding T cell damage by antibody and complement in patients with SLE, the role of a mechanism involving antibody in the absence ofcomplement, antibody-dependent cellmediated cytotoxicity (ADCC), has been less carefully explored. In this paper, we have therefore asked whether anti-T cell antibodies in the plasma of patients with SLE were capable of exerting such cytotoxic effects on normal T cells as well as on their own T cells. We found that most plasma of patients with active SLE had anti-T cell antibodies, which, in the absence ofcomplement, could mediate T cell damage in the presence of mononuclear cells.
METHODS
Plasma of the patients with SLE. All patients met the preliminary criteria proposed by the American Rheumatism Association for the diagnosis of SLE. Clinical activity was assessed at the time of blood drawing by two physicians on the basis of signs and symptoms (active rash, serositis, arthritis, active central nervous system disease, and active renal disease). Patients lacking these symptoms or detectable signs of activity were categorized as inactive. The active patients in this study had at least two ofthe above criteria ofactivity.Moreover, all active patients had large quantities of anti-DNA antibodies.
At the time blood was obtained for these studies, patients with active disease had not yet received any treatment. In some instances blood was also drawn from these same patients at a later time when their disease had become inactive. Inactive patients had previously been treated with corticosteroids and occasionally with azathioprine, but were not receiving such treatment at the time of study. In addition, such patients had little detectable anti-DNA antibodies.
All the SLE plasma used had been frozen once and had not been previously thawed. Normal fresh frozen plasma was obtained from healthy adults. All 1640 supplemented with 10% heat-inactivated fetal calf serum. The plate was incubated for 6 h at 37°C in a humidified atmosphere containing 5% CO2. Although the effector-totarget cell (E/T) ratio usually used was 25:1, in some experiments this ratio was varied. This method is called the "preculture method."
In some experiments the T cells were first 5'Cr-labeled, and then the SLE or normal plasma was added together with the effector cells; the plasma was present continuously (at a concentration of 20%) during the 6-h cytotoxic assay. This is called the "co-culture method."
The percent cytotoxicity was calculated as follows: at the end of the incubation period, the plates were centrifuged at 300 g for 10 min, a 100-,ul portion of the supernate was removed from each well, and its radioactivity was counted in a gamma spectrometer. Maximum possible 51Cr release was determined by three freeze-thaw cycles. The spontaneous release from wells without effector cells was also determined: To analyze why this result was observed, we incubated unfractionated effector cells overnight at 4°C with a concentration ofpurified IgG equal to that which would be present in 40% plasma (see above). These cells were then washed three times and used in the ADCC assay at various E/T ratios. As shown in Fig. 3 , such treatment ofthe effector cells markedly diminished their capacity to mediate ADCC. One explanation for this result is that "cold" T cells in the effector population become coated with anti-T cell antibodies and inhibit by a cold target mechanism. To determine directly whether this was the case, the following experiment was perfbrmed. Here various numbers of T cells, preincubated with IgG fraction of SLE plasma but which were not radiolabeled, were added to the standard ADCC system. T cells not treated with the IgG fraction of SLE plasma were used as a control. As shown in Fig. 4 the addition of IgG-treated cold T cells markedly inhibited the ADCC. For this reason all further experiments were performed using the preculture method in which the T cells were first treated with SLE plasma and then washed.
Comparison ofADCC and CDC using SLE plasma. 14 normal plasma, 8 plasma from inactive SLE patients, and 9 plasma from active SLE patients were tested for ADCC activity. The percent cytotoxicity (mean± SE) for these three groups was 1.4+0.4, 2.6±0.5, and 11.6+2.0, respectively. The active SLE group was significantly different from the other two groups, P < 0.01. The upper limit (the mean ±2 SD) of normal subjects, 4.4%, was used as the upper limit ofnormal. By this criterion, eight of nine active SLE plasma showed significant ADCC (Fig. 5A) . In contrast, all eight inactive SLE plasma tested for ADCC activity produced cytotoxicity levels that were within normal limits. These results demonstrate that normal T lymphocytes can be destroyed by autologous unfractionated mononuclear cells in the absence ofcomplement when these T cells are pretreated with the plasma of active SLE patients.
The same labeled target T cells used as targets for ADCC were also used for the simultaneous measurement ofCDC (5'Cr release technique) using some ofthe above plasma (individually numbered 1-7). The normal and inactive SLE plasma showed no cytotoxicity. However, plasma from the five patients with active SLE studied showed a CDC of 11.2±0.8% cytotoxicity (P < 0.01 compared with the other two groups) (Fig. 5B) . When CDC induced by seven of these plasma was measured by dye exclusion techniques, all the plasmas from active patients caused significant cytotoxicity, whereas only one plasma from an inactive SLE patient showed cytotoxicity (Fig. 5C) some of the more sensitive cells; therefore, they may not be present during the actual 6-h 5'Cr release assay.
Comparison ofADCC mediated by active plasma and inactive plasmafrom the same patient with SLE. ADCC activity of three pairs of plasma from patients with active SLE was compared with the ADCC activity using plasma from the same patients when they were inactive (Fig. 6) . A fourth pair ofplasma came from identical twins discordant with regard to disease activity. These results revealed that plasma of SLE patients supported significant ADCC activity when obtained in the active phase but not in the inactive phase of disease. Reproducibility of ADCC with different T cell donors. Three active SLE plasma were studied for their ADCC activity against T lymphocytes from three unrelated normal subjects. As shown in Table I , these Specificity and antibody nature of the factor in the SLE plasma leading to cell-mediated lysis. IgG has been implicated as the major antibody class involved in ADCC, though several investigators reported that IgM antibody could also induce ADCC (27, 28) . To determine whether the effective fraction of SLE plasma that mediated ADCC was an antibody of the IgG or IgM class, the IgG and IgM fractions of three patients with SLE and one normal individual were obtained by gel filtration and used for ADCC. First, the plasma and plasma fractions were tested for anti-T cell antibody by dye exclusion (Table II) . Patient I was active and had anti-T cell antibodies of the IgM class as measured by CDC. Patient II was mildly active, and patient III had inactive SLE. No antibodies were present in the plasma of these latter two patients or the normal individual by this method of CDC. Fig. 7 shows the results ofADCC using unfractionated and fractionated plasma from these three patients. In patient I, higher ADCC activity was found in the IgG fraction than in unfractionated plasma; the IgM fraction showed minimal ADCC activity despite containing most of the antibody active in CDC. In patients II and III, ADCC activity was shown only with the IgG fraction, and not in unfractionated plasma. Neither the IgG nor the IgM fraction from plasma from a normal individual could mediate ADCC. These results suggest that IgG was the major antibody class effective in our cell-mediated assay of ADCC.
The use of effector cells and target cells from patients with SLE. To help establish the relevance of an ADCC mechanism to the lymphopenia and immune (29, 30) . To determine whether our cell-mediated cytotoxicity was also inhibited by aggregated IgG, several concentrations of aggregated IgG were added to our system. As shown in Fig. 9 , ADCC activities observed in two active SLE plasma were inhibited in a dose-response fashion by aggregated IgG. (Fig. 7) . This is consistent with the finding of Longmire et al. (43) , who found that an IgG fraction from supernates of cultured spleen lymphocytes from patients with Hodgkin's disease could also mediate ADCC against autologous T lymphocytes. We assume that most patients with active SLE have both IgM and IgG anti-T cell antibodies. However, plasma from patient 7 in Fig. 5 demonstrated a high level of CDC and no ADCC activity. In this patient it is possible that only anti-T cell antibodies ofthe IgM class were present.
In the course of our studies we observed cases in which unfractionated plasma from patients with SLE could not mediate ADCC but in which the IgG fraction could. The presence of inhibiting immune complexes in the unfractionated plasma might explain these observations. The possibility is supported by the finding that aggregated IgG could inhibit ADCC by whole plasma. In addition, our observation that the ADCC assay performed in the continuous presence of SLE plasma (co-culture method) failed to show high levels of ADCC, whereas preincubation of the target cells with plasma followed by washing (preculture method) produced higher levels of ADCC, might also be explained by the presence of immune complexes in some of these plasma. In this regard, several other investigators have noted that SLE sera also suppressed ADCC activity of normal human peripheral blood mononuclear cells against Chang cells or chicken erythrocytes (34, (44) (45) (46) (47) . Another reason for the failure of the co-culture method is that unlabeled T cells present in the effector cell population could have interacted with the anti-T cell antibody in the SLE plasma; here "cold target inhibition" could have occurred, and, thus, could have reduced the degree of ADCC observed. Indeed the results ofthe experiments shown in Figs. 3 and 4 support these ideas. In addition, antibodies to the effector cells of ADCC may have also inhibited the reaction when plasma was co-cultured throughout the ADCC reaction.
Of interest was the fact that the IgG fraction of the plasma of patients II and III (Table II and Fig. 7 ) with inactive disease could mediate ADCC in the absence of demonstrable complement-mediated cytotoxicity. Thus, ADCC activity may be a very sensitive method to detect anti-T cell antibodies in patients with inactive disease and with low levels of anti-T cell antibodies.
We have not yet studied functional impairments that might be produced by a cytotoxic ADCC mechanism. However, a previous study has suggested that a subpopulation ofT cells may be removed selectively by the ADCC mechanism (42) . Moreover, Twomey et al. (16) , using unfractionated plasma, and Sagawa and Abdou (18) , using the IgG fraction of SLE sera, could, in the absence of complement, inhibit the development of concanavalin A-induced suppressor function. These observations could be explained by such an ADCC mechanism selectively eliminating suppressor T cells. Finally, whereas complement-dependent lymphocytotoxicity mediated by IgM is optimally observed at temperatures from 40 to 150C (14) , ADCC appears to work effectively at higher temperatures. Thus, it is possible that at body temperature ADCC may be an important mechanism by which regulatory T cell subsets are deleted in patients with SLE.
